Indegene shares gained over 4% on Wednesday, June 12, after the company informed the stock exchanges about its strategic collaboration with the Indian Institute of Science (IISc) and Ignite Life Science Foundation.
The company, in a stock exchange filing, said that IISc, Bengaluru, and Ignite Life Science Foundation (LSF), a Bengaluru-based science philanthropy, have joined hands with Indegene to advance scientific discoveries in India.
G Mugesh a professor at IISc said that the development paves the way for accelerating scientific innovation. “We are excited to collaborate with Indegene and Ignite and appreciate their support. This is a great step forward in advancing scientific discoveries in India and paves the way for accelerating scientific innovation in the coming days”, Mugesh said.
The company mentioned in a release that Professor Mugesh’s work is focused on the prevention of cardiovascular and neurodegenerative diseases. Indegene and Ignite Life Science Foundation have supported IISc with a new multimode plate reader with absorbance, fluorescence, and luminescence capabilities, according to the release.
TS Balganesh, a member of Ignite’s Scientific Advisory Board said that the multimode plate reader provided by Indegene and Ignite LSF can give new insights in the realm of research.
The company also highlighted the need for advancing scientific discoveries in the cardiovascular and neurodegenerative diseases space, stating that cardiovascular and neurodegenerative diseases affect millions of people worldwide.
Indegene’s consolidated revenue from operations for the March quarter stood at ₹673 crore, an increase of over 6% compared to ₹632.2 crore in the same quarter of the corresponding fiscal. The company’s net profit for the March quarter grew by more than 94% to ₹94.8 crore compared to ₹48.8 crore on a year-on-year basis.
The research services provider’s revenue from operations for the March quarter fell marginally by 0.05% compared to ₹673.4 crore in the quarter ended December. The company’s net profit for the March quarter fell by 4% from ₹98.8 crore in the quarter ended December.
Indegene’s revenue from operations for FY24 grew 12% to ₹2,589.6 crore compared to ₹2,306.1 crore in the preceding fiscal. The company’s net profit for FY24 grew more than 26% to ₹336.7 crore from ₹266.1 crore in FY23.
Shares of Indegene Ltd traded 4.54% higher at ₹587 apiece at 2.50 pm.
Also Read: Suzlon Dividend in May 2025? Here's what the management said
The company, in a stock exchange filing, said that IISc, Bengaluru, and Ignite Life Science Foundation (LSF), a Bengaluru-based science philanthropy, have joined hands with Indegene to advance scientific discoveries in India.
G Mugesh a professor at IISc said that the development paves the way for accelerating scientific innovation. “We are excited to collaborate with Indegene and Ignite and appreciate their support. This is a great step forward in advancing scientific discoveries in India and paves the way for accelerating scientific innovation in the coming days”, Mugesh said.
The company mentioned in a release that Professor Mugesh’s work is focused on the prevention of cardiovascular and neurodegenerative diseases. Indegene and Ignite Life Science Foundation have supported IISc with a new multimode plate reader with absorbance, fluorescence, and luminescence capabilities, according to the release.
TS Balganesh, a member of Ignite’s Scientific Advisory Board said that the multimode plate reader provided by Indegene and Ignite LSF can give new insights in the realm of research.
“The multiplate reader will increase throughput and accelerate experiments. Rich biological data can drive the generation of new insights and open up fresh areas for investigation” Balganesh said.
The company also highlighted the need for advancing scientific discoveries in the cardiovascular and neurodegenerative diseases space, stating that cardiovascular and neurodegenerative diseases affect millions of people worldwide.
Indegene’s consolidated revenue from operations for the March quarter stood at ₹673 crore, an increase of over 6% compared to ₹632.2 crore in the same quarter of the corresponding fiscal. The company’s net profit for the March quarter grew by more than 94% to ₹94.8 crore compared to ₹48.8 crore on a year-on-year basis.
The research services provider’s revenue from operations for the March quarter fell marginally by 0.05% compared to ₹673.4 crore in the quarter ended December. The company’s net profit for the March quarter fell by 4% from ₹98.8 crore in the quarter ended December.
Indegene’s revenue from operations for FY24 grew 12% to ₹2,589.6 crore compared to ₹2,306.1 crore in the preceding fiscal. The company’s net profit for FY24 grew more than 26% to ₹336.7 crore from ₹266.1 crore in FY23.
Shares of Indegene Ltd traded 4.54% higher at ₹587 apiece at 2.50 pm.
Also Read: Suzlon Dividend in May 2025? Here's what the management said
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
